Procter & Gamble Health Limited (PGHL.BO)
INR 5104.95
(-0.72%)
INR 5104.95
(-0.72%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.09 Billion INR | -19.14% |
| 2022 | 1.34 Billion INR | 17.13% |
| 2021 | 1.15 Billion INR | -2.67% |
| 2020 | 1.18 Billion INR | -12.96% |
| 2019 | 1.36 Billion INR | 19.98% |
| 2018 | 1.13 Billion INR | -28.14% |
| 2017 | 1.57 Billion INR | -3.78% |
| 2016 | 1.63 Billion INR | 0.08% |
| 2015 | 1.63 Billion INR | -7.62% |
| 2014 | 1.77 Billion INR | 16.8% |
| 2013 | 1.51 Billion INR | 15.93% |
| 2012 | 1.3 Billion INR | 15.8% |
| 2011 | 1.13 Billion INR | 85.03% |
| 2010 | 611.2 Million INR | 4.5% |
| 2009 | 584.9 Million INR | -19.85% |
| 2008 | 729.8 Million INR | 101.1% |
| 2007 | 362.9 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q4 | 1.09 Billion INR | 0.0% |
| 2023 FY | 1.09 Billion INR | -19.14% |
| 2023 Q2 | 1.29 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.34 Billion INR | 17.13% |
| 2022 Q4 | 1.34 Billion INR | 0.0% |
| 2022 Q2 | 1.67 Billion INR | 0.0% |
| 2021 Q2 | 1.42 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 1.15 Billion INR | 0.0% |
| 2021 FY | 1.15 Billion INR | -2.67% |
| 2020 Q2 | 1.08 Billion INR | 0.0% |
| 2020 Q4 | 1.18 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 1.18 Billion INR | -12.96% |
| 2019 FY | 1.36 Billion INR | 19.98% |
| 2018 FY | 1.13 Billion INR | -28.14% |
| 2018 Q2 | 1.13 Billion INR | 0.0% |
| 2018 Q4 | 1.3 Billion INR | 0.0% |
| 2017 Q2 | 1.57 Billion INR | 0.0% |
| 2017 FY | 1.57 Billion INR | -3.78% |
| 2017 Q4 | 1.18 Billion INR | 0.0% |
| 2016 FY | 1.63 Billion INR | 0.08% |
| 2016 Q4 | 1.81 Billion INR | 0.0% |
| 2016 Q2 | 1.63 Billion INR | 0.0% |
| 2015 FY | 1.63 Billion INR | -7.62% |
| 2015 Q2 | 1.63 Billion INR | 0.0% |
| 2015 Q4 | 1.54 Billion INR | 0.0% |
| 2014 Q4 | 1.97 Billion INR | 0.0% |
| 2014 Q2 | 1.77 Billion INR | 0.0% |
| 2014 FY | 1.77 Billion INR | 16.8% |
| 2013 Q4 | 1.73 Billion INR | 0.0% |
| 2013 Q2 | 1.51 Billion INR | 0.0% |
| 2013 FY | 1.51 Billion INR | 15.93% |
| 2012 FY | 1.3 Billion INR | 15.8% |
| 2012 Q2 | 1.3 Billion INR | 0.0% |
| 2012 Q4 | 1.68 Billion INR | 0.0% |
| 2011 FY | 1.13 Billion INR | 85.03% |
| 2011 Q4 | 2.17 Billion INR | 0.0% |
| 2011 Q2 | 1.13 Billion INR | 0.0% |
| 2010 FY | 611.2 Million INR | 4.5% |
| 2009 FY | 584.9 Million INR | -19.85% |
| 2008 FY | 729.8 Million INR | 101.1% |
| 2007 FY | 362.9 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 93.361% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 98.888% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 83.632% |
| Granules India Limited | 13 Billion INR | 91.61% |
| Indoco Remedies Limited | 3.53 Billion INR | 69.096% |
| Achyut Healthcare Limited | 568 Thousand INR | -191995.07% |
| Ajanta Pharma Limited | 8.28 Billion INR | 86.828% |
| Alkem Laboratories Limited | 26.61 Billion INR | 95.9% |
| Alpa Laboratories Limited | 136.65 Million INR | -698.446% |
| Brooks Laboratories Limited | 96.1 Million INR | -1035.285% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 52.12% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 24.249% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 7.883% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 98.283% |
| Eris Lifesciences Limited | 1.89 Billion INR | 42.28% |
| FDC Limited | 3.88 Billion INR | 71.943% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 95.658% |
| Gufic Biosciences Limited | 2 Billion INR | 45.576% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -943.346% |
| Ipca Laboratories Limited | 24.71 Billion INR | 95.585% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -627.546% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -1013.776% |
| Lasa Supergenerics Limited | 190.43 Million INR | -472.954% |
| Laurus Labs Limited | 18.45 Billion INR | 94.087% |
| Lupin Limited | 49.53 Billion INR | 97.797% |
| Mankind Pharma Limited | 15.53 Billion INR | 92.976% |
| Medicamen Biotech Limited | 593.75 Million INR | -83.764% |
| Medico Remedies Limited | 163.37 Million INR | -567.862% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | 84.424% |
| Piramal Pharma Limited | 21.75 Billion INR | 94.985% |
| RPG Life Sciences Limited | 1.01 Billion INR | -8.03% |
| Sigachi Industries Limited | 707.2 Million INR | -54.283% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 98.894% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 52.806% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -417.563% |
| Unichem Laboratories Limited | 7.04 Billion INR | 84.516% |
| Wanbury Limited | 360.23 Million INR | -202.888% |
| Windlas Biotech Limited | 621.89 Million INR | -75.449% |
| ZIM Laboratories Limited | 812.62 Million INR | -34.268% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 96.83% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 96.573% |
| Hester Biosciences Limited | 755.81 Million INR | -44.362% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -277.482% |
| Bal Pharma Limited | 878.11 Million INR | -24.255% |
| Strides Pharma Science Limited | 11.26 Billion INR | 90.312% |
| Venus Remedies Limited | 1.21 Billion INR | 10.338% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 83.027% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 84.614% |
| Shilpa Medicare Limited | 3.44 Billion INR | 68.367% |
| Aarti Drugs Limited | 4.85 Billion INR | 77.544% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 74.317% |
| Suven Life Sciences Limited | 7.08 Million INR | -15300.141% |
| Ind-Swift Limited | 640.91 Million INR | -70.241% |
| Valiant Laboratories Limited | 100.15 Million INR | -989.422% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 78.287% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 69.666% |
| Themis Medicare Limited | 705.74 Million INR | -54.603% |
| Hikal Limited | 3.03 Billion INR | 64.075% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 95.212% |
| Sequent Scientific Limited | 3.46 Billion INR | 68.486% |
| Novartis India Limited | 448.6 Million INR | -143.223% |
| Wockhardt Limited | 6.4 Billion INR | 82.952% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 91.539% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -4179.327% |
| Neuland Laboratories Limited | 3.5 Billion INR | 68.863% |
| Morepen Laboratories Limited | 2.48 Billion INR | 56.109% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -2635.958% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 11.752% |